Clinical management of amyloid cardiomyopathy-Reference-Cited by-同舟云学术

Clinical management of amyloid cardiomyopathy

Published:2021-09-01 Issue: Volume: Page:
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Kim Morris M.^ORCID,Kolseth Clinton M.,Carlson Dayna,Masri Ahmad

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10741-021-10159-w.pdf

Reference75 articles.

1. Abraham B et al (2020) Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol 125(1):92–99

2. Miles JA et al (2019) Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med (Hagerstown) 20(6):379–388

3. Hunt SA et al (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391-479

4. Abraham WT et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–666

5. Young JB et al (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618–2626

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Diagnosis and Treatment of AL Cardiac Amyloidosis;Current Treatment Options in Cardiovascular Medicine;2024-08-02

2. Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial;Journal of the American Heart Association;2023-08

3. Treatment of Transthyretin Amyloidosis;Amyloidosis and Fabry Disease;2023

4. Cardiogenic Shock Due to Atrial Arrhythmia as the Initial Presentation of Transthyretin Cardiac Amyloidosis;JACC: Case Reports;2022-11